Abstract 125P
Background
Bevacizumab biosimilar (Avegra®) became available for patients in Russia since 2015. Since introduction, no real-world data except clinical cases was available. We decided to assess the safety and effectiveness of Avegra® in patients treated in daily practice according to national treatment protocols. Depending on the geography the study was divided into Apollon-11, conducted in Moscow, and Soyuz-Apollon, conducted in 18 regions of Russia. The final analysis summarizes pooled results of all regions.
Methods
This multicentre prospective observational post-authorization study of bevacizumab biosimilar combined with chemotherapy in patients with metastatic colorectal cancer was conducted in 28 centres in Russia from December 2019 to January 2023. Patients with metastatic colorectal cancer (mCRC), treated with bevacizumab at a dose of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with standard chemotherapy regimens as a first line of therapy were included. Primary safety endpoints were the incidence of adverse reactions (ARs) related to bevacizumab and the rate of treatment discontinuation due to ARs.
Results
438 patients with mCRC in 28 research centres of the Russian Federation were included in the study. Median age of patients was 62 (28–87) years, ECOG performance status of £1. Most of the tumors were left-sided (67.8%) and had at least one RAS/BRAF mutation (55.9%). After median follow-up of 7.3 months, adverse reactions occurred in 11%, of which 2.7% were grade ³3. Treatment was discontinued in 2.8% of patients due to adverse reactions. Objective response was achieved in 37.9% of patients (95% CI 31.4 - 41.6) with 2.8% of complete responses. Median progression-free survival was 9.4 months (95% CI 8.1 - 10.7). Median overall survival was not reached.
Conclusions
Our findings are consistent with previously known bevacizumab safety and efficacy profile. Numerically low incidence of ARs is most likely due to reduced reporting of adverse events in real-world clinical practice settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BIOCAD.
Funding
BIOCAD.
Disclosure
A. Tryakin, M. Fedyanin, F.V. Moiseenko: Financial Interests, Personal, Coordinating PI: BIOCAD. M. Mariam, O. Mironov, D. Stroyakovskiy, N. Sokolov, S. Orlova, E. Mantsyrev, A.V. Sultanbaev, A. Teterich, K. Babina, D. Yukalchuk, S. Borzyanitsa, A. Isyangulova, A. Saidullaeva, I. Chernova, E. Bobrova, N. Fadeeva: Financial Interests, Personal, Local PI: BIOCAD.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract